Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) is anticipated to release its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect Nektar Therapeutics to post earnings of ($0.17) per share and revenue of $15.61 million for the quarter.
Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last posted its earnings results on Wednesday, March 12th. The biopharmaceutical company reported $0.15 EPS for the quarter, beating the consensus estimate of ($0.18) by $0.33. The company had revenue of $29.18 million for the quarter, compared to the consensus estimate of $36.65 million. Nektar Therapeutics had a negative return on equity of 173.28% and a negative net margin of 180.70%. On average, analysts expect Nektar Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Nektar Therapeutics Price Performance
NKTR traded down $0.03 during trading on Tuesday, hitting $0.66. The stock had a trading volume of 238,819 shares, compared to its average volume of 1,813,380. The company has a 50 day moving average price of $0.73 and a 200-day moving average price of $0.92. Nektar Therapeutics has a one year low of $0.43 and a one year high of $1.93. The firm has a market cap of $122.27 million, a price-to-earnings ratio of -0.77 and a beta of 0.62.
Analyst Ratings Changes
Several brokerages have weighed in on NKTR. William Blair reiterated a "market perform" rating on shares of Nektar Therapeutics in a research note on Thursday, March 13th. StockNews.com began coverage on shares of Nektar Therapeutics in a report on Wednesday, April 16th. They set a "hold" rating on the stock. B. Riley initiated coverage on shares of Nektar Therapeutics in a research note on Wednesday, January 8th. They issued a "buy" rating and a $4.00 price objective for the company. Jefferies Financial Group raised shares of Nektar Therapeutics from a "hold" rating to a "buy" rating and boosted their target price for the stock from $1.00 to $2.00 in a research note on Friday, April 11th. Finally, HC Wainwright restated a "buy" rating and set a $6.50 price objective on shares of Nektar Therapeutics in a research report on Thursday, March 13th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $4.50.
View Our Latest Stock Report on NKTR
Nektar Therapeutics Company Profile
(
Get Free Report)
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.
See Also
Before you consider Nektar Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nektar Therapeutics wasn't on the list.
While Nektar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
